alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>


<ARTICLE>                     5
<CIK>                         0000813621
<NAME>                        AMCOL International Corporation
<MULTIPLIER>                                   1,000
<CURRENCY>                                     USD

<S>                                            <C>
<PERIOD-TYPE>                                  9-MOS
<FISCAL-YEAR-END>                              DEC-31-1999
<PERIOD-START>                                 JAN-1-1999
<PERIOD-END>                                   SEP-30-1999
<EXCHANGE-RATE>                                1.00
<CASH>                                         5,472
<SECURITIES>                                   0
<RECEIVABLES>                                  113,065
<ALLOWANCES>                                   4,493
<INVENTORY>                                    40,522
<CURRENT-ASSETS>                               164,650
<PP&E>                                         347,685
<DEPRECIATION>                                 174,440
<TOTAL-ASSETS>                                 364,483
<CURRENT-LIABILITIES>                          62,203
<BONDS>                                        0
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       320
<OTHER-SE>                                     0
<TOTAL-LIABILITY-AND-EQUITY>                   364,483
<SALES>                                        414,147
<TOTAL-REVENUES>                               414,147
<CGS>                                          314,203
<TOTAL-COSTS>                                  372,775
<OTHER-EXPENSES>                               804
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             5,264
<INCOME-PRETAX>                                35,304
<INCOME-TAX>                                   12,709
<INCOME-CONTINUING>                            22,863
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   22,863
<EPS-BASIC>                                  .85
<EPS-DILUTED>                                  .84


</TABLE>
# L_2018221EN.01000201.xml

| 31.8.2018 | EN | Official Journal of the European Union | L 221/2 |
| --- | --- | --- | --- |

31.8.2018

EN

Official Journal of the European Union

L 221/2

---

COMMISSION IMPLEMENTING REGULATION (EU) 2018/1210

of 30 August 2018

on the minimum selling price for skimmed milk powder for the 23rd partial invitation to tender within the tendering procedure opened by Implementing Regulation (EU) 2016/2080

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EU) No 1308/2013 of the European Parliament and of the Council of 17 December 2013 establishing a common organisation of the markets in agricultural products and repealing Council Regulations (EEC) No 922/72, (EEC) No 234/79, (EC) No 1037/2001 and (EC) No 1234/2007 (1),

Having regard to Commission Implementing Regulation (EU) 2016/1240 of 18 May 2016 laying down rules for the application of Regulation (EU) No 1308/2013 of the European Parliament and of the Council with regard to public intervention and aid for private storage (2), and in particular Article 32 thereof,

Whereas:

| (1) | Commission Implementing Regulation (EU) 2016/2080 (3) has opened the sale of skimmed milk powder by a tendering procedure. |
| --- | --- |

(1)

Commission Implementing Regulation (EU) 2016/2080 (3) has opened the sale of skimmed milk powder by a tendering procedure.

| (2) | In the light of the tenders received for the 23rd partial invitation to tender, a minimum selling price should be fixed. |
| --- | --- |

(2)

In the light of the tenders received for the 23rd partial invitation to tender, a minimum selling price should be fixed.

| (3) | The measures provided for in this Regulation are in accordance with the opinion of the Committee for the Common Organisation of the Agricultural Markets, |
| --- | --- |

(3)

The measures provided for in this Regulation are in accordance with the opinion of the Committee for the Common Organisation of the Agricultural Markets,

HAS ADOPTED THIS REGULATION:

Article 1

For the 23rd partial invitation to tender for the selling of skimmed milk powder within the tendering procedure opened by Implementing Regulation (EU) 2016/2080, in respect of which the period during which tenders were to be submitted ended on 28 August 2018, the minimum selling price shall be 123 EUR/100 kg.

Article 2

This Regulation shall enter into force on the day of its publication in the Official Journal of the European Union.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 30 August 2018.

For the Commission,

On behalf of the President,

Jerzy PLEWA

Director-General

Directorate-General for Agriculture and Rural Development

---

(1)  
  OJ L 347, 20.12.2013, p. 671.

1

(2)  
  OJ L 206, 30.7.2016, p. 71.

2

(3)  Commission Implementing Regulation (EU) 2016/2080 of 25 November 2016 opening the sale of skimmed milk powder by a tendering procedure (OJ L 321, 29.11.2016, p. 45).

3

---
Exhibit 4.3


 


Consent of Independent Registered
Public Accounting Firm


We consent to the
reference made to our firm under the caption “Independent Registered Public Accounting Firm” in Part B of the Prospectus
and to the use of our report dated April 26, 2017, in this Registration Statement (Form S-6 No. 333-215957) of Smart Trust 314,
comprising Smart Trust, Smart Ten Trust, Series 8.


 


/s/ Grant
Thornton LLP


 


Chicago, Illinois


April 26, 2017
----

----

**                                  DOR      BIOPHARMA,      INC.**

| November                14, 2007 | by:    | **/s/                Christopher J. Schaber**        |
|----------------------------------|--------|------------------------------------------------------|
|                             |   | Christopher                J. Schaber, Ph.D.         |
|                             |   | President                and Chief Executive Officer |
|                             |   | (Principal                Executive Officer)         |
|                             |   |                                                 |
Editorial Note on Part 172
Editorial Note: Nomenclature changes to part 172 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; 70 FR 72074, Dec. 1, 2005; and 81 FR 49896, July 29, 2016.

§ 172.535 Disodium inosinate. The food additive disodium inosinate may be safely used in food in accordance with the following prescribed conditions: ( a ) The food additive is the disodium salt of inosinic acid, manufactured and purified so as to contain no more than 150 parts per million of soluble barium in the compound disodium inosinate with seven and one-half molecules of water of crystallization.
( b ) The food additive is used as a flavoring adjuvant in food.
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          MAR-26-2000
<PERIOD-START>                             MAR-29-1999
<PERIOD-END>                               JUN-27-1999
<CASH>                                             664
<SECURITIES>                                         0
<RECEIVABLES>                                    7,303
<ALLOWANCES>                                         0
<INVENTORY>                                      6,626
<CURRENT-ASSETS>                                14,980
<PP&E>                                          91,538
<DEPRECIATION>                                (84,412)
<TOTAL-ASSETS>                                  22,562
<CURRENT-LIABILITIES>                           14,933
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            35
<OTHER-SE>                                      72,681
<TOTAL-LIABILITY-AND-EQUITY>                    22,562
<SALES>                                         10,630
<TOTAL-REVENUES>                                10,630
<CGS>                                            8,063
<TOTAL-COSTS>                                    8,063
<OTHER-EXPENSES>                                 3,129
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 336
<INCOME-PRETAX>                                  (898)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                              (898)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     (898)
<EPS-BASIC>                                      (.29)
<EPS-DILUTED>                                    (.29)


</TABLE>
IV 

115TH CONGRESS 

1ST SESSION H. RES. 67 

Expressing support for designation of November 2017, as ‘‘National Bladder 

Health Month’’. 

IN THE HOUSE OF REPRESENTATIVES 

JANUARY 27, 2017 

Mr. ENGEL (for himself, Ms. MENG, Mrs. LAWRENCE, and Mr. LANGEVIN) 

submitted the following resolution; which was referred to the Committee 

on Oversight and Government Reform 

RESOLUTION 

Expressing support for designation of November 2017, as 

‘‘National Bladder Health Month’’. 

Whereas tens of millions of people in the United States are 

affected by bladder diseases and conditions including urinary incontinence, overactive bladder, underactive bladder, interstitial cystitis, nocturia, urinary tract infections, 

bladder cancer, urotrauma, and neurogenic bladder; 

Whereas bladder diseases and conditions have a significant 

impact on health and quality of life, contributing to decreased physical activity (which can increase obesity levels and risk of diabetes and cardiovascular disease), depression, social isolation, falls, sexual dysfunction, loss of 

self-esteem, hospitalizations, nursing home admissions, 

and even death; 


SSpencer on DSK4SPTVN1PROD with BILLS
2 

•HRES 67 IH 

Whereas bladder diseases and conditions result in costs to the 

United States economy estimated at more than 

$70,000,000,000 annually; 

Whereas bladder problems are highly stigmatized, and open 

dialogue generated by Bladder Health Month can reduce 

stigma and empower providers and patients to have 

much-needed conversations about bladder health; 

Whereas medical and behavioral research to better understand and maintain bladder health and treat bladder diseases is critically needed, yet poorly recognized; 

Whereas bladder diseases and conditions are common in military veterans; 

Whereas more than 1 in 10 military servicemembers injured 

in Afghanistan and Iraq have ‘‘urotrauma’’ injuries 

(damage to the urinary tract or reproductive organs); 

Whereas 1 in 3 younger women veterans report overactive 

bladder, stress urinary incontinence, and painful bladder 

symptoms; 

Whereas more than 3⁄4 of veterans with spinal cord injury 

suffer from neurogenic bladder; 

Whereas bladder cancer is the fourth most commonly diagnosed cancer among Veterans Affairs (VA) Health System patients; 

Whereas preventative campaigns and measures for diseases 

and conditions this extensive and expensive are routine 

and accepted in common medical, societal, and public 

health practice, yet none exists in a large, systematic 

fashion for bladder health; and 

Whereas November 2017 would be an appropriate month to 

designate as ‘‘National Bladder Health Month’’ since 


SSpencer on DSK4SPTVN1PROD with BILLS
3 

•HRES 67 IH 

bladder health awareness has been promoted in November for more than 20 years: Now, therefore, be it 

1 Resolved, That the House of Representatives supports 

2 the designation of ‘‘National Bladder Health Month’’. 

Æ 


SSpencer on DSK4SPTVN1PROD with BILLS
Searched for **https://www.stb.gov/**

 

19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

*Note:* This calendar view maps the number of captures of **https://www.stb.gov/**, *not* how many times the site was actually updated.

Look Up URL in general Internet Archive web collection.
# L_2019129DE.01009001.xml

| 17.5.2019 | DE | Amtsblatt der Europäischen Union | L 129/90 |
| --- | --- | --- | --- |

17.5.2019

DE

Amtsblatt der Europäischen Union

L 129/90

---

Berichtigung der Delegierten Verordnung (EU) 2018/64 der Kommission vom 29. September 2017 zur Ergänzung der Verordnung (EU) 2016/1011 des Europäischen Parlaments und des Rates durch die Festlegung, wie die in Artikel 20 Absatz 1 Buchstabe c Ziffer iii genannten Kriterien anzuwenden sind, wenn beurteilt wird, ob bestimmte Ereignisse in einem oder mehreren Mitgliedstaaten erhebliche nachteilige Auswirkungen auf die Integrität der Märkte, die Finanzstabilität, die Verbraucher, die Realwirtschaft oder die Finanzierung der Haushalte und Unternehmen hätten

(
  Amtsblatt der Europäischen Union L 12 vom 17. Januar 2018
  )

Seite 6, Artikel 2 Buchstabe c:

Anstatt:

„[...], wobei sowohl die absoluten Zahlen als auch der Anteil am Gesamtwert der in diesen Mitgliedstaaten zum Vertrieb zugelassenen oder angemeldeten Investmentfonds zu betrachten sind;“

muss es heißen:

„[...], wobei sowohl die absoluten Zahlen als auch der Anteil am Gesamtwert der in diesen Mitgliedstaaten zugelassenen oder zum Vertrieb angemeldeten Investmentfonds zu betrachten sind;“.

---
Order filed February 10, 2015 

In The

Fourteenth Court of Appeals

NO. 14-15-00015-CV

IN THE INTEREST OF C.C.G., A CHILD

On Appeal from the 315th District Court

Harris County, Texas

Trial Court Cause No. 2013-03557J

O R D E R

The notice of appeal in this case was filed January 6, 2015. The clerk’s 

record was filed January 15, 2015. To date, the filing fee of $195.00 has not been 

paid. No evidence that appellant has established indigence has been filed. See Tex. 

R. App. P. 20.1. Therefore, the court issues the following order. 

Appellant is ordered to pay the filing fee in the amount of $195.00 to the 

Clerk of this court on or before February 25, 2015. See Tex. R. App. P. 5. If 

appellant fails to timely pay the filing fee in accordance with this order, the appeal 

will be dismissed.

PER CURIAM
Editorial Note on Part 172
Editorial Note: Nomenclature changes to part 172 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; 70 FR 72074, Dec. 1, 2005; and 81 FR 49896, July 29, 2016.

§ 172.830 Succinylated monoglycerides. The food additive succinylated monoglycerides may be safely used in food in accordance with the following prescribed conditions: ( a ) The additive is a mixture of semi-and neutral succinic acid esters of mono- and diglycerides produced by the succinylation of a product obtained by the glycerolysis of edible fats and oils, or by the direct esterification of glycerol with edible fat-forming fatty acids.
( b ) The additive meets the following specifications: Succinic acid content: 14.8%-25.6% Melting point: 50 °C-60 °C. Acid number: 70-120
( c ) The additive is used or intended for use in the following foods: ( 1 ) As an emulsifier in liquid and plastic shortenings at a level not to exceed 3 percent by weight of the shortening.
( 2 ) As a dough conditioner in bread baking, when such use is permitted by an appropriate food standard, at a level not to exceed 0.5 percent by weight of the flour used.
Exhibit
      32





Certification
      Pursuant to


18
      U.S.C.
      Section 1350,


as
      Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002





Pursuant
      to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
      Act of 2002, the undersigned officers of Medialink Worldwide Incorporated (the
      "Company"), hereby certify to such officers’ knowledge, that the Company's
      Quarterly Report on Form 10-Q for the quarter ended September 30, 2008 (the
      "Report") fully complies with the requirements of Section 13(a) or 15(d), as
      applicable, of the Securities Exchange Act of 1934 and that the information
      contained in the Report fairly presents, in all material respects, the financial
      condition and results of operations of the Company.





Dated:
      November 14, 2008





/s/
                Laurence MoskowitzName:
                Laurence MoskowitzTitle:
                Chief Executive Officer/s/
                Kenneth G. TorosianName:
                Kenneth G. TorosianTitle:
                Chief Financial Officer





The
      foregoing certification is being furnished solely pursuant to 18 U.S.C. § 1350,
      as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
      2002.
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
      This schedule contains summary financial information extracted from the
consolidated financial statements and is qualified in its entirety by reference
to such financial statements.
</LEGEND>
<MULTIPLIER>                                   1

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                               MAY-31-2000
<PERIOD-START>                                   JUN-1-1999
<PERIOD-END>                                    MAY-31-2000
<CASH>                                                1,258
<SECURITIES>                                              0
<RECEIVABLES>                                             0
<ALLOWANCES>                                              0
<INVENTORY>                                               0
<CURRENT-ASSETS>                                      1,258
<PP&E>                                                    0
<DEPRECIATION>                                            0
<TOTAL-ASSETS>                                        7,445
<CURRENT-LIABILITIES>                               180,422
<BONDS>                                                   0
<PREFERRED-MANDATORY>                                     0
<PREFERRED>                                               0
<COMMON>                                             18,775
<OTHER-SE>                                                0
<TOTAL-LIABILITY-AND-EQUITY>                          7,445
<SALES>                                                   0
<TOTAL-REVENUES>                                          0
<CGS>                                                     0
<TOTAL-COSTS>                                             0
<OTHER-EXPENSES>                                    372,354
<LOSS-PROVISION>                                          0
<INTEREST-EXPENSE>                                        0
<INCOME-PRETAX>                                     327,354
<INCOME-TAX>                                          6,600
<INCOME-CONTINUING>                                       0
<DISCONTINUED>                                            0
<EXTRAORDINARY>                                           0
<CHANGES>                                                 0
<NET-INCOME>                                        378,954
<EPS-BASIC>                                            0.30
<EPS-DILUTED>                                          0.30



</TABLE>
|   | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |   |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------|--------|

|   | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented in the Report. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | By: /s/   John P. Broderick                         |   |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
|   | John P. Broderick                                                                                                                                                                          |   |
|   | Chief Executive and Financial Officer                                                                                                                                                      |   |
|   | (Principal Financial and Accounting Officer)                                                                                                                                               |   |
|   | March 31, 2010                                                                                                                                                                             |   |
<PAGE>

EXHIBIT 11.1



EAGLE POINT SOFTWARE CORPORATION AND SUBSIDIARY
CONSOLIDATED STATEMENT REGARDING COMPUTATION OF NET EARNINGS PER SHARE
--------------------------------------------------------------------------------

<TABLE>
<CAPTION>
                                                                                     Years Ended
                                                                   2001              2000             1999
                                                                --------------------------------------------
<S>                                                             <C>               <C>              <C>
SHARES USED IN DETERMINING BASIC EARNINGS PER SHARE:

Weighted average common shares outstanding                      4,711,664         4,846,488        4,826,785
                                                                =========         =========        =========


SHARES USED IN DETERMINING DILUTED EARNINGS PER SHARE:

Weighted average common shares outstanding                      4,711,664         4,846,488        4,826,785

Net effect of stock options based on the treasury stock
  method using the average market price during the period               0                 0          157,862
                                                                ---------         ---------        ---------
     Total weighted average common and common equivalent
        shares outstanding                                      4,711,664         4,846,488        4,984,647
                                                                =========         =========        =========
</TABLE>

                                     -76-
Exhibit No. 23.1

 

 

Consent of Independent Registered Public Accounting Firm

 

The Board of Directors

BNCCORP, Inc.:

We consent to the incorporation by reference in the registration statements (No. 333-130556, 333-03512, 333-98647, 333-58584, 333-130559) on Form S-8 of BNCCORP, Inc. of our report dated March 26, 2007, with respect to the consolidated balance sheets of BNCCORP, Inc. as of December 31, 2006 and 2005, and the related consolidated statements of income, stockholders’ equity and comprehensive income, and cash flows, for each of the years in the three-year period ended December 31, 2006, which report appears in the December 31, 2006, annual report on Form 10-K of BNCCORP, Inc.

 

(signed) KPMG LLP

Minneapolis, Minnesota

March 26, 2007